Targeting CD38, a type II glycoprotein highly expressed on several B cell subsets including short and long lived plasma cells, may provide another approach to target autoantibody production; however, studies are yet to assess anti-CD38 therapy in SSc (160). Here, CD38 is linked to systemic sclerosis.